portola pharmaceuticals inc menu about us executives board of directors scientific advisory board collaborations business development pipeline andexanet alfa cerdulatinib sykspecific inhibitors products bevyxxa® healthcare professionals about vte medical information requests medical education grants careers college internships total rewards program staffing agencies and recruiters media investors innovative science patient focused innovative science patient focused innovative science patient focused about us developing and commercializing therapies that advance patient care in thrombosis and other hematologic diseases read more pipeline andexxa cerdulatinib sykspecific inhibitors read more now approved learn more about bevyxxa® betrixaban read more welcome to yogasana lorem ipsum dolor sit amet consectetur adipiscing elit ut ut mauris et magna suscipit egestas eu eu ipsum phasellus hendrerit ac ex ut aliquam donec lacinia rutrum sem et luctus urna egestas vitae cras consequat ante sed pharetra accumsan massa enim faucibus neque ac scelerisque metus nisl fermentum tellus ut ut condimentum felis nulla quis nulla nulla donec placerat tincidunt ex nunc dictum enim arcu id fermentum urna rhoncus ac morbi non tortor eget sem ultrices fringilla vel sit amet turpis quisque tincidunt enim et aliquam ultrices nunc odio ullamcorper sapien ac accumsan arcu est in lectus pellentesque nisl libero finibus et turpis a mattis suscipit nibh etiam dignissim odio a tincidunt molestie est orci laoreet urna vitae egestas dui mi eu quam morbi non dictum libero quisque non molestie dolor vestibulum maximus magna et luctus porta nulla facilisi more info our classes yoga mantra lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more meditation lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more deep release lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more reltaxation lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more   portola pharmaceuticals inc all rights reservedcontact us      terms of use      privacy policy portola pharmaceuticals inc menu about us executives board of directors scientific advisory board collaborations business development pipeline andexanet alfa cerdulatinib sykspecific inhibitors products bevyxxa® healthcare professionals about vte medical information requests medical education grants careers college internships total rewards program staffing agencies and recruiters media investors innovative science patient focused innovative science patient focused innovative science patient focused about us developing and commercializing therapies that advance patient care in thrombosis and other hematologic diseases read more pipeline andexxa cerdulatinib sykspecific inhibitors read more now approved learn more about bevyxxa® betrixaban read more welcome to yogasana lorem ipsum dolor sit amet consectetur adipiscing elit ut ut mauris et magna suscipit egestas eu eu ipsum phasellus hendrerit ac ex ut aliquam donec lacinia rutrum sem et luctus urna egestas vitae cras consequat ante sed pharetra accumsan massa enim faucibus neque ac scelerisque metus nisl fermentum tellus ut ut condimentum felis nulla quis nulla nulla donec placerat tincidunt ex nunc dictum enim arcu id fermentum urna rhoncus ac morbi non tortor eget sem ultrices fringilla vel sit amet turpis quisque tincidunt enim et aliquam ultrices nunc odio ullamcorper sapien ac accumsan arcu est in lectus pellentesque nisl libero finibus et turpis a mattis suscipit nibh etiam dignissim odio a tincidunt molestie est orci laoreet urna vitae egestas dui mi eu quam morbi non dictum libero quisque non molestie dolor vestibulum maximus magna et luctus porta nulla facilisi more info our classes yoga mantra lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more meditation lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more deep release lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more reltaxation lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more   portola pharmaceuticals inc all rights reservedcontact us      terms of use      privacy policy pipeline  portola pharmaceuticals inc menu about us executives board of directors scientific advisory board collaborations business development pipeline andexanet alfa cerdulatinib sykspecific inhibitors products bevyxxa® healthcare professionals about vte medical information requests medical education grants careers college internships total rewards program staffing agencies and recruiters media investors pipelineandexanet alfa cerdulatinib sykspecific inhibitors pipeline we discover and develop novel therapeutics to meet patient needs in thrombosis other hematologic disorders and inflammation   portola pharmaceuticals inc all rights reservedcontact us      terms of use      privacy policy executives  portola pharmaceuticals inc menu about us executives board of directors scientific advisory board collaborations business development pipeline andexanet alfa cerdulatinib sykspecific inhibitors products bevyxxa® healthcare professionals about vte medical information requests medical education grants careers college internships total rewards program staffing agencies and recruiters media investors about usexecutives board of directors scientific advisory board collaborations business development executives   william lis   chief executive officer john t curnutte md phd executive vice president research and development   mardi c dier   executive vice president chief financial officer   tao fu   executive vice president chief commercial and business officer william lis chief executive officer william lis joined portola in  as chief business officer and chief operating officer and was appointed chief executive officer in may  with over  years of biopharmaceutical experience under his leadership portola has advanced several novel compounds into clinical development successfully raised over  billion in private and public financings including an initial public offering in  and executed multiple partnerships for its programs mr lis previously held positions at scios inc a johnson  johnson company where he last served as vice president business and commercial operations having successfully inlicensed and led strategic development and commercial launch operations for xarelto® rivaroxaban prior to joining scios he was senior director of marketing and new products for millennium pharmaceuticals inc previously cor therapeutics inc where he managed integrilin® eptifibatide marketing and project leadership for preclinical programs earlier in his career he was involved in the us sales launch and commercialization of several products including lovenox® enoxaparin while at rhonepoulenc rorer mr lis holds a bs from the university of maryland back to top john t curnutte md phdexecutive vice president research and development john curnutte md joined portola as executive vice president research and development in  prior to joining portola dr curnutte served as chief executive officer of v biosciences a private startup company founded in  with the goal of developing hostdirected antiviral small molecules before that he served as president at scheringplough biopharma formerly dnax research institute and now merck research laboratories where he led the drug discovery and early development efforts for biologic therapeutics during his time with scheringplough eight therapeutic entities progressed into development including five small molecules and one gene therapy construct in the immunology and oncology therapeutic areas earlier in his career he held several senior management positions at genentech during which he oversaw that company’s immunology discovery program prior to genentech dr curnutte was a tenured faculty member at the scripps research institute pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies dr curnutte received an undergraduate degree in biochemistry and molecular biology from harvard university and an md and a phd in biological chemistry from harvard medical school he is currently an adjunct clinical professor of pediatrics at stanford university school of medicine and a member of the medical staff where he continues to consult on patients with primary immunodeficiencies dr curnutte is a member of the board of directors of diadexus inc a company focused on cardiovascular diagnostics back to top mardi c dierexecutive vice president chief financial officer mardi dier joined portola in august  as senior vice president and chief financial officer and has served as executive vice president and chief financial officer since november  ms dier is responsible for leading the corporate finance accounting and information technology functions and is a member of the company’s executive leadership team ms dier brings to portola nearly  years of experience in the life sciences industry  during her tenure at portola she has successfully led a series of private public and alternative financings  previously she served as vice president of investor relations at chiron corporation from  until its acquisition by novartis pharmaceuticals in april  prior to joining chiron she served as a director in the west coast investment banking practice at prudential securities where she focused on client development equity underwriting and mergers and acquisitions for biotechnology and other life sciences companies prior to prudential ms dier was at kpmg peat marwick in the audit department she holds a bs in biology from stanford university and an mba from the anderson school at the university of california los angeles back to top tao fuexecutive vice president chief commercial and business officer tao fu joined portola pharmaceuticals in june  with  years of experience in business development commercial strategy and management consulting in the biopharmaceutical industry prior to joining portola he was vice president and head of mergers and acquisitions and alliance management at bristolmyers squibb where he was responsible for the company’s corporate development alliance management and venture activities previously he was vice president business development at janssen johnson  johnson where he was responsible for over  business development transactions including the execution of the us license and collaboration agreement with bayer for xarelto® rivaroxaban earlier in his career he held positions at scios inc a johnson  johnson company mckinsey  company and becton dickinson mr fu holds an ms in biology from the university of rochester and an mba in finance and marketing from vanderbilt university he completed his undergraduate studies at tsinghua university and is a chartered financial analyst cfa back to top   portola pharmaceuticals inc all rights reservedcontact us      terms of use      privacy policy portola pharmaceuticals inc menu about us executives board of directors scientific advisory board collaborations business development pipeline andexanet alfa cerdulatinib sykspecific inhibitors products bevyxxa® healthcare professionals about vte medical information requests medical education grants careers college internships total rewards program staffing agencies and recruiters media investors innovative science patient focused innovative science patient focused innovative science patient focused about us developing and commercializing therapies that advance patient care in thrombosis and other hematologic diseases read more pipeline andexxa cerdulatinib sykspecific inhibitors read more now approved learn more about bevyxxa® betrixaban read more welcome to yogasana lorem ipsum dolor sit amet consectetur adipiscing elit ut ut mauris et magna suscipit egestas eu eu ipsum phasellus hendrerit ac ex ut aliquam donec lacinia rutrum sem et luctus urna egestas vitae cras consequat ante sed pharetra accumsan massa enim faucibus neque ac scelerisque metus nisl fermentum tellus ut ut condimentum felis nulla quis nulla nulla donec placerat tincidunt ex nunc dictum enim arcu id fermentum urna rhoncus ac morbi non tortor eget sem ultrices fringilla vel sit amet turpis quisque tincidunt enim et aliquam ultrices nunc odio ullamcorper sapien ac accumsan arcu est in lectus pellentesque nisl libero finibus et turpis a mattis suscipit nibh etiam dignissim odio a tincidunt molestie est orci laoreet urna vitae egestas dui mi eu quam morbi non dictum libero quisque non molestie dolor vestibulum maximus magna et luctus porta nulla facilisi more info our classes yoga mantra lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more meditation lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more deep release lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more reltaxation lorem ipsum dolor sit amet consectetur adipiscing elit vivamus nec massa sodales mattis lorem et pharetra nulla sed a metus hendrerit read more   portola pharmaceuticals inc all rights reservedcontact us      terms of use      privacy policy portola pharmaceuticals inc nasdaqptla trading up  insiders are selling  highlight press highlight pressbreaking tech news entertainment mortgages and more portola pharmaceuticals inc nasdaqptla trading up – insiders are selling july   by clarence martin tweet        advertisement here is the rundown on market activity for portola pharmaceuticals inc nasdaqptla tao fu evp cbo disclosed the sale of  shares of ptla the shares were purchased at an average price of  fu now owns  of the stock according to the sec filing john t curnutte evp disclosed the sale of  shares of ptla stock the shares were sold on july th for an average price of  the evp now owns  of the stock per the form  sec filing evp mardi dier disclosed the sale of  shares the shares were sold on july th for an average price of  the evp now owns  of the stock per the form  sec filing portola pharmaceuticals inc launched on september   is a biopharmaceutical company the company is focused on the development and commercialization of therapeutics in the areas of thrombosis other hematologic disorders and inflammation for patients having limited or no approved treatment options the business’s two lead programs betrixaban and andexanet alfa address unmet medical needs in the area of thrombosis or blood clots its third product candidate is cerdulatinib the business’s spleen tyrosine kinase syk is a mediator of immune response in various types of immune cells the company has a program of selective syk inhibitors one of which is partnered with ora inc here are a few additional firms who have increased or decreased their stake in ptla harvey capital management inc downsized its investment by selling  shares a decrease of  harvey capital management inc currently owns  shares worth  the total value of its holdings increased  nisa investment advisors llc bolstered its ownership by buying  shares an increase of  in the quarter nisa investment advisors llc controls  shares with a value of  the value of the position overall is up by  as of quarter end howe  rusling inc had disposed of  shares trimming its holdings by  the value of the investment in ptla increased from  to  a change of  since the last quarter as of the end of the quarter meeder asset management inc had sold a total of  shares trimming its stake by  the value of the company’s investment in portola pharmaceuticals inc went from  to  decreasing  quarter over quarter equity analyst citigroup both downgraded the stock and lowered the price target on august  changing the price objective from  to  and altering the rating from “buy” to “neutral” on august  the company was downgraded to “neutral” from “buy” and a price target of  was set in a report from citigroup on august  credit suisse left the stock rating at “neutral” and lowered the price expectation to  from  august  investment analysts at morgan stanley kept the stock rating at “neutral” but lowered the price expectation from  to  credit suisse downgraded the stock and lowered the price target on may  cutting the price target from  to  and changing the rating from “outperform” to “neutral” on may  the stock rating was downgraded from “outperform” to “neutral” with a current price target of  in a statement from credit suisse the company is up from yesterday’s close of  it is currently trading at  slightly over  the stock’s  day moving average and which is slightly above the  day moving average of  the  day moving average moved up  whereas the  day moving average was up  or  as of the last earnings report the eps was  and is estimated to be  for the current year with  shares presently outstanding analysts expect next quarter’s eps to be  with next year’s eps anticipated to be          advertisement         advertisement mortgage rate updates mortgage rates looking better at hsbc quicken friday jul   … read morefriday’s rates for home mortgages at us bank chase bank jul  us bankcorpthe benchmark  year loan interest rates are  at  yielding an apr of … read morecommerce bank bmo harris bank interest rates for home mortgages jul  commerce bankthe benchmark  year loan interest rates are coming out at  at commerce … read morebank of america bbt friday’s mortgage rates jul  bbt bank year frms are available starting at  at bbt corp nysebbt today carrying … read more sports lonzo ball’s latest footwear has well and truly floppedhere’s a question – would all the social media hype and celebrity endorsements in the world encourage you to spend  on a pair of basketball … read moresuper bowl winners to pocket  per player – taxfreeit’s long been known that the tax returns of professional athletes are just about as complex as it gets this is because not only do they have to pay … read more top news business technology sports entertainment life mortgages also in the news… about us writers advertise with us contact us reuters technology news half of german companies hit by sabotage spying in last two years bsi saysprivate equity bid for paysafe stokes payments ma boomarista loses bid to lift import ban in cisco battle highlight press is a participant in the amazon services llc associates program an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to amazoncom insider trading activity portola pharmaceuticals inc nasdaqptla – evp sold  shares of stock  market exclusive sign in join home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps sign in welcomelog into your accountyour usernameyour password forgot your password sign up welcomeregister for an account your emailyour username a password will be emailed to you password recovery recover your passwordyour email search sign in  joinmy account orders sign inwelcome log into your accountyour usernameyour password forgot your password get helpcreate an account create an accountwelcome register for an accountyour emailyour username a password will be emailed to you password recoveryrecover your passwordyour email a password will be emailed to you market exclusive home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps home insider trading insider trading activity portola pharmaceuticals inc nasdaqptla – evp sold  shares insider trading insider trading activity portola pharmaceuticals inc nasdaqptla – evp sold  shares of stock byme staff july    share on facebook tweet on twitter insider trading activity for portola pharmaceuticals inc nasdaqptla tao fu  evp of portola pharmaceuticals inc nasdaqptla reportedly sold  shares of the company’s stock at an average price of  for a total transaction amount of  sec form insider trading history for portola pharmaceuticals inc nasdaqptla on  mauritius pte ltd maxwell major shareholder bought  with an average share price of  per share and the total transaction amounting to view sec filing on  charles j homcy director sold  with an average share price of  per share and the total transaction amounting to view sec filing on  mardi dier cfo sold  with an average share price of  per share and the total transaction amounting to view sec filing on  mardi dier cfo sold  with an average share price of  per share and the total transaction amounting to view sec filing on  jean jacques bienaime director sold  with an average share price of  per share and the total transaction amounting to view sec filing on  william lis ceo sold  with an average share price of  per share and the total transaction amounting to view sec filing on  william lis ceo sold  with an average share price of  per share and the total transaction amounting to view sec filing analyst ratings for portola pharmaceuticals inc nasdaqptlathese are  hold ratings  buy ratings the current consensus rating for portola pharmaceuticals inc nasdaqptla is buy score  with a consensus target price of   a potential  downside analyst ratings history for portola pharmaceuticals inc nasdaqptla on  goldman sachs group inc the reiterated rating neutral with a price target of  to  on  cibc upgraded rating market perform to outperform on  citigroup inc boost price target of rating buy with a price target of  to  on  william blair reiterated rating outperform on  cowen and company boost price target of rating outperform with a price target of  to  on  oppenheimer holdings inc boost price target of rating outperform with a price target of  to  on  morgan stanley boost price target of rating overweight with a price target of  to  recent trading activity for portola pharmaceuticals inc nasdaqptlashares of portola pharmaceuticals inc closed the previous trading session at  up   with  shares trading hands please enable javascript to view the comments powered by disqusan ad to help with our costs related articlesmore from author insider trading activity portola pharmaceuticals inc nasdaqptla – insider sold  shares of stock insider trading activity overstockcom inc nasdaqostk – insider sold  shares of stock insider trading activity nutanix inc nasdaqntnx – vp sold  shares of stock insider trading activity netapp inc nasdaqntap – evp sold  shares of stock insider trading activity nektar therapeutics nasdaqnktr – svp sold  shares of stock insider trading activity mma capital management llc nasdaqmmac – ceo bought  shares of stock subscribe to our newsletter email  first namelast nameemail a word from the sponsor latest articles pingtan marine enterprise ltd nasdaqpme files an k results of operations and financial condition rayonier advanced materials inc nyseryam files an k financial statements and exhibits armstrong world industries inc nyseawi files an k submission of matters to a vote of security holders recent posts insider trading activity portola pharmaceuticals inc nasdaqptla – evp sold  shares of stock insider trading activity portola pharmaceuticals inc nasdaqptla – insider sold  shares of stock insider trading activity overstockcom inc nasdaqostk – insider sold  shares of stock insider trading activity nutanix inc nasdaqntnx – vp sold  shares of stock insider trading activity netapp inc nasdaqntap – evp sold  shares of stock sponsored editor picks here’s what just happened with sarepta therapeutics inc nasdaqsrpt july   biotech movers vertex pharmaceuticals incorporated nasdaqvrtx and inovio pharmaceuticals inc nasdaqino july   here’s what just happened with puma biotechnology inc nasdaqpbyi and cymabay july   popular posts this small nasdaq hidden gem may have a b drug july   weekly biotech report covering – opko health inc nyseopk intercept april   facebook inc – nasdaqfb might be moving away from its april   popular categorysec filingslsestockstech newsbiotech stocksstock market newsanalyst ratingssmall capscanada about usmarket exclusive offers the latest financial news and analysis for selected us stocks and securities we are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions at market exclusive we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices market exclusive is not a registered investment brokerdealer the content on this site is for informational purposes only additionally the content on this site does not represent the views of market exclusive and is solely a representation of the authors who publish them before investing in any security you should do your own due diligence and consult with a registered broker or financial advisorcontact us email protectedfollow us sec filings stocks stock market news tech news biotech stocks featured small caps gold other news oil become a contributor about marketexclusivecom contributors advertise on market exclusive contact us  market exclusive  portola pharmaceuticals inc nasdaqptla trading up – insiders and institutional investors selling finance dailydaily markets commodities personal finance and economic newsportola pharmaceuticals inc nasdaqptla trading up – insiders and institutional investors selling july   by ted blackburn tweet         advertisement portola pharmaceuticals inc nasdaqptla has been the object of insider selling activity recently evp mardi dier disclosed the sale of  shares of ptla the shares were sold on july th for an average price of  dier now owns  of the stock per the form  sec filing william lis ceo reported the sale of  shares of ptla stock the shares sold for  the ceo now owns  of the stock according to the sec filing mardi dier evp disclosed the sale of  shares the shares were purchased at an average price of  dier now owns  of the stock according to the sec filing portola pharmaceuticals inc launched on september   is a biopharmaceutical company the company is focused on the development and commercialization of therapeutics in the areas of thrombosis other hematologic disorders and inflammation for patients having limited or no approved treatment options the business’s two lead programs betrixaban and andexanet alfa address unmet medical needs in the area of thrombosis or blood clots its third product candidate is cerdulatinib the business’s spleen tyrosine kinase syk is a mediator of immune response in various types of immune cells the company has a program of selective syk inhibitors one of which is partnered with ora inc these firms have also modified their investment in ptla howe  rusling inc trimmed its holdings by selling  shares a decrease of  in the quarter howe  rusling inc currently owns  shares valued at  the value of the position overall is up by  as of the end of the quarter meeder asset management inc had sold  shares trimming its holdings by  the value of the investment in ptla decreased from  to  a change of  since the last quarter as of quarter end creative planning had disposed of a total of  shares trimming its stake by  the value of the total investment in portola pharmaceuticals inc went from  to  decreasing  for the reporting period as of quarter end next financial group inc had sold  shares trimming its position  the value of the investment in portola pharmaceuticals inc went from  to  a change of  quarter to quarter        advertisement on august  the company was downgraded from “buy” to “neutral” with a current price target of  in a statement from citigroup august  investment analysts at credit suisse left the stock rating at “neutral” and lowered the price expectation from  to  on august  morgan stanley kept the company rating at “neutral” but lowered the price expectation to  from  equity analyst citigroup both downgraded the stock and lowered the price target on august  cutting the price target from  to  and moving the rating from “buy” to “neutral” credit suisse downgraded the stock and lowered the price target on may  changing the price objective from  to  and changing the rating from “outperform” to “neutral” on may  the stock rating was downgraded to “neutral” from “outperform” and a price target of  was set in a report from credit suisse the company is now up by  percent from yesterday’s close shares are trading at  just a bit higher than the  day moving average which is  and which is slightly above the  day moving average of  the  day moving average was up  and the  day average went up by  in the last earnings report the eps was  and is expected to be  for the current year with  shares now outstanding next quarter’s eps is estimated at  and the next full year eps is anticipated to be          advertisement tweetrevenue generating websites international business machines ibm reached a week highinsiders selling short interest growing euronet worldwide inc nasdaqeeftshares now down at  mat mattel opens east coast distribution…ebay inc ebay – citigroup holds rating and sets new price targetwns holdings limited sponsore wns – citigroup maintains rating and updates price targetdeutsche bank keeps rating and raises price target on bank of new york mellon corpora bkjp morgan downgrades rating on continental resources inc clr markets economy peertopeer loans growing in popularity among consumersincrease in young american adults not owning credit cards for various reasons credit  loans citizens bank wells fargo mortgage interest rates improve today jul  wells fargo year frm interest rates at wells fargo nysewfc start at  and an apr of   the typically lower … read more categories breaking technology auto health personal finance economy mortgage about fi daily home staff privacy policy contact us accessibility terms of use reuters business news ford to petition to avoid us recall of  million vehiclesglobal pizza brands battle for russias farflung regionsge shares fall as profit slumps investors await new ceos targetswall st retreats from record levels as ge disappointscrimean scandal prompts siemens to retreat from russian energy portola pharmaceuticals inc ptlao company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile portola pharmaceuticals inc ptlao related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse ptlao on nasdaq usd pm edt change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description portola pharmaceuticals inc incorporated on september   is a biopharmaceutical company the company is focused on the development and commercialization of therapeutics in the areas of thrombosis other hematologic disorders and inflammation for patients having limited or no approved treatment options the companys two lead programs betrixaban and andexanet alfa address unmet medical needs in the area of thrombosis or blood clots its third product candidate is cerdulatinib the companys spleen tyrosine kinase syk is a mediator of immune response in various types of immune cells the company has a program of selective syk inhibitors one of which is partnered with ora incbetrixabanbetrixaban is an oral oncedaily inhibitor of factor xa in development for extended duration venous thromboembolism vte prophylaxis in acute medically ill patients for  days of inhospital and postdischarge use acute medically ill patients are those hospitalized for serious nonsurgical conditions such as heart failure stroke infection rheumatic disorders and pulmonary disorders its phase iii apex study is designed to use biomarkers to identify and enroll patients to benefit from therapy with betrixabanandexanet alfaandexanet alfa is an orphan drug which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fxa inhibitor andexanet alfa has shown indications for patients anticoagulated with a direct or indirect fxa inhibitor when reversal of anticoagulation is needed such as in uncontrolled bleeding or for emergency surgery or urgent procedures andexanet alfa is a therapy to demonstrate reversal of the anticoagulant activity of fxa inhibitors as measured by antifxa levels the company has completed over two phase iii annexa andexanet alfa an antidote to the anticoagulant effects of fxa inhibitors studies the company has also completed a series of phase ii proofofconcept studies evaluating the safety and activity of andexanet alfa in healthy volunteerscerdulatinibthe company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation cerdulatinib is an orally available dual kinase inhibitor that inhibits syk and janus kinase jak enzymes that regulate important signaling pathways the company is developing cerdulatinib for treatment of certain bcell hematologic cancers the company is conducting a phase iiia proofofconcept study of cerdulatinib in nonhodgkin lymphoma nhl and chronic lymphocytic leukemia cll patientsthe company competes with bristolmyers squibb company bayer pharma ag and janssen pharmaceuticals inc » full overview of ptlao company address portola pharmaceuticals inc  east grand avenue suite south san francisco   ca    p f  company web links home page officers  directors name compensation hollings renton  william lis  mardi dier  john curnutte  tao fu  » more officers  directors portola pharmaceuticals inc news portola shares soar after fda approves clot preventing drug jun   update portola shares soar after fda approves clot preventing drug jun   us fda approves portola bloodthinner to prevent blood clots jun   briefportola pharmaceuticals interim data from a phase a study evaluating cerdulatinib jun   briefportola pharmaceuticals reports q loss per share  may   » more ptlao news related topics stocksstock screenerhealthcarebiotechnology  medical research portola pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report portola pharmaceuticals inc  product pipeline review   published by global markets direct product code  published march   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license portola pharmaceuticals inc  product pipeline review   published march   content info  pages description summary global markets directs portola pharmaceuticals inc  product pipeline review   provides an overview of the portola pharmaceuticals incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of portola pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of portola pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of portola pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the portola pharmaceuticals incs pipeline products reasons to buy evaluate portola pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of portola pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the portola pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of portola pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of portola pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of portola pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures portola pharmaceuticals inc snapshot portola pharmaceuticals inc overview key information key facts portola pharmaceuticals inc  research and development overview key therapeutic areas portola pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy portola pharmaceuticals inc  pipeline products glance portola pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities portola pharmaceuticals inc  clinical stage pipeline products phase i productscombination treatment modalities portola pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities portola pharmaceuticals inc  drug profiles andexanet alfa product description mechanism of action rd progress betrixaban product description mechanism of action rd progress cerdulatinib product description mechanism of action rd progress prt product description mechanism of action rd progress prt product description mechanism of action rd progress portola pharmaceuticals inc  pipeline analysis portola pharmaceuticals inc  pipeline products by target portola pharmaceuticals inc  pipeline products by route of administration portola pharmaceuticals inc  pipeline products by molecule type portola pharmaceuticals inc  pipeline products by mechanism of action portola pharmaceuticals inc  recent pipeline updates portola pharmaceuticals inc  dormant projects portola pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles betrixaban elinogrel potassium prt portola pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables portola pharmaceuticals inc key information portola pharmaceuticals inc key facts portola pharmaceuticals inc  pipeline by indication  portola pharmaceuticals inc  pipeline by stage of development  portola pharmaceuticals inc  monotherapy products in pipeline  portola pharmaceuticals inc  phase iii  portola pharmaceuticals inc  phase i  portola pharmaceuticals inc  preclinical  portola pharmaceuticals inc  pipeline by target  portola pharmaceuticals inc  pipeline by route of administration  portola pharmaceuticals inc  pipeline by molecule type  portola pharmaceuticals inc  pipeline products by mechanism of action  portola pharmaceuticals inc  recent pipeline updates  portola pharmaceuticals inc  dormant developmental projects portola pharmaceuticals inc  discontinued pipeline products  list of figures portola pharmaceuticals inc  pipeline by top  indication  portola pharmaceuticals inc  pipeline by stage of development  portola pharmaceuticals inc  monotherapy products in pipeline  portola pharmaceuticals inc  pipeline by top  target  portola pharmaceuticals inc  pipeline by top  route of administration  portola pharmaceuticals inc  pipeline by top  molecule type  portola pharmaceuticals inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved portola pharmaceuticals inc nasdaqptla portola pharmaceuticals inc ptla product news news  stocknewscom     follow us stocktwits twitter portola pharmaceuticals inc ptla product news news ptla – company announces fda has accepted the new drug application for priority review  ema validated the marketing authorization application for the oral factor xa inhibitor anticoagulant betrixaban pdufa date of june   dec    pm  by stocknewscom staff product news key facts surrounding this news item ptla had a powr rating of d sell coming into today ptla was  below its day moving average coming into today ptla was  above its day moving average coming into today ptla was  below its day moving average coming into today ptla was  below its day moving average coming into today ptla was  below its day moving average coming into today ptla had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about portola pharmaceuticals inc ptla portola pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases the company was founded in  and is based in south san francisco california view our full ptla ticker page with ratings news and more ptla at a glance ptla current powr rating™ overall powr rating™ ptla current price   more ptla ratings data and news ptla price reaction the day of this event dec  ptla closing price ptla volume from avgleading up to this eventptla mo returnafter this eventptla day returnptla day returnptla day return ptla price chart more portola pharmaceuticals inc ptla news view all eventdate symbol news detail start price end price change powr rating loading please wait view all ptla news page generated in  seconds ptlanasdaq gs stock quote  portola pharmaceuticals inc  bloomberg markets error could not add to watchlist x  watchlist portola pharmaceuticals inc ptlaus nasdaq gs usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  analysts actions  danaher goldman sachs goodyear wendys and more  the street  portola pharmaceuticals inks m royalty deal  investopedia there are currently no news stories for this ticker please check back later  liberty allstarr growth fund inc june  update  portola pharmaceuticals announces upcoming data presentations on betrixaban and andexanet alfa at the international society on  biotech stocks showing signs of resurgence  us fda approves bevyxxa® betrixaban first and only anticoagulant for hospital and extended duration prevention of venous  portola pharmaceuticals presents interim phase a safety and efficacy data for cerdulatinib at the international congress of ma  portola pharmaceuticals announces phase a safety and efficacy cerdulatinib data to be presented at the european hematology ass  portola pharmaceuticals announces cerdulatinib data to be presented at the international conference on malignant lymphoma icml  portola pharmaceuticals reports first quarter  financial results and provides corporate update  portola pharmaceuticals to announce first quarter  financial results and host conference call on monday may   portola pharmaceuticals announces betrixaban and andexxa™ andexanet alfa presentations at acc there are currently no press releases for this ticker please check back later profile portola pharmaceuticals inc provides specialty pharmaceutical products the company offers novel therapeutics for thrombosis hematologic disorders and inflammation portola pharmaceuticals serves customers in the united states address  east grand avenuesouth san francisco ca united states phone  website wwwportolacom executives board members william lis chief executive officer mardi c dier exec vpcfo tao fu exec vpchief commercial  bus ofcr john t curnutte exec vpresearch  dev pamela b conley vpresearch biology show more portola pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports portola pharmaceuticals inc  product pipeline review  portola pharmaceuticals inc  product pipeline review   wgr  march  global  pages global markets direct description table of content sample report enquiry before buy related reports portola pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘portola pharmaceuticals inc  product pipeline review  ’ provides an overview of the portola pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of portola pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of portola pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of portola pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the portola pharmaceuticals inc’s pipeline productsreasons to buy evaluate portola pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of portola pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the portola pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of portola pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of portola pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of portola pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures portola pharmaceuticals inc snapshot portola pharmaceuticals inc overview key information key facts portola pharmaceuticals inc  research and development overview key therapeutic areas portola pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy portola pharmaceuticals inc  pipeline products glance portola pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities portola pharmaceuticals inc  clinical stage pipeline products phase i productscombination treatment modalities portola pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities portola pharmaceuticals inc  drug profiles andexanet alfa product description mechanism of action rd progress betrixaban product description mechanism of action rd progress cerdulatinib product description mechanism of action rd progress prt product description mechanism of action rd progress prt product description mechanism of action rd progress portola pharmaceuticals inc  pipeline analysis portola pharmaceuticals inc  pipeline products by target portola pharmaceuticals inc  pipeline products by route of administration portola pharmaceuticals inc  pipeline products by molecule type portola pharmaceuticals inc  pipeline products by mechanism of action portola pharmaceuticals inc  recent pipeline updates portola pharmaceuticals inc  dormant projects portola pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles betrixaban elinogrel potassium prt portola pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesportola pharmaceuticals inc key information portola pharmaceuticals inc key facts portola pharmaceuticals inc  pipeline by indication  portola pharmaceuticals inc  pipeline by stage of development  portola pharmaceuticals inc  monotherapy products in pipeline  portola pharmaceuticals inc  phase iii  portola pharmaceuticals inc  phase i  portola pharmaceuticals inc  preclinical  portola pharmaceuticals inc  pipeline by target  portola pharmaceuticals inc  pipeline by route of administration  portola pharmaceuticals inc  pipeline by molecule type  portola pharmaceuticals inc  pipeline products by mechanism of action  portola pharmaceuticals inc  recent pipeline updates  portola pharmaceuticals inc  dormant developmental projects portola pharmaceuticals inc  discontinued pipeline products  list of figuresportola pharmaceuticals inc  pipeline by top  indication  portola pharmaceuticals inc  pipeline by stage of development  portola pharmaceuticals inc  monotherapy products in pipeline  portola pharmaceuticals inc  pipeline by top  target  portola pharmaceuticals inc  pipeline by top  route of administration  portola pharmaceuticals inc  pipeline by top  molecule type  portola pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft portola pharmaceuticals ptla  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in portola pharmaceuticals inc ptla median target price   downside positive ratings  of  analysts latest  morgan stanley  overweight     view all analyst ratings for ptla » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up »